Altimmune ($ALT) Misleading Pemvidutide Trial Results and Fibrosis Endpoint Failure Case

• $ALT investors filed a claim against Altimmune for overstating the success of its Phase 2b trial for pemvidutide, misleading investors about fibrosis outcomes, and concealing statistical weaknesses in trial design that inflated expectations.

• After revealing the drug failed to improve fibrosis significantly and analysts called the data “underwhelming,” $ALT dropped 53.2% on June 26, 2025.

• $ALT investors can join this case to be notified about potential recovery.

Case Details:

Between August 10, 2023, and June 25, 2025, Altimmune repeatedly claimed pemvidutide had strong potential to treat MASH (Metabolic Dysfunction-Associated Steatohepatitis), citing expectations of both MASH resolution and fibrosis reduction. The company described its IMPACT trial as a key value driver and highlighted favorable biomarker trends during interim updates.

In reality, the company’s trial design allowed for a high placebo response, which ultimately undermined statistical significance. On June 26, 2025, Altimmune reported that while the drug met the MASH resolution endpoint, it failed to achieve statistical significance for fibrosis reduction, the primary concern of regulators and investors.

$ALT collapsed 53.2% that day.

Based on these events, $ALT investors filed a claim against Altimmune, alleging the company:

• It misled investors about the strength and design of its clinical trial for pemvidutide.

• It overstated the likelihood of hitting key efficacy endpoints, especially fibrosis.

• It artificially inflated its stock value ahead of the disappointing Phase 2b readout.

Investors argue Altimmune concealed weaknesses in its trial and misrepresented clinical expectations to maintain its valuation.